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Abstract Stem cell transplantation consists in the intro-
duction of stem cells or derived products in a diseased
organism. Because of the differentiation properties of stem
cells, the goal is to replace damaged cells or tissues.
Numbers of stem cell were identified and isolated from
embryos, fetuses, or adult organs, harboring different
properties, and thus providing multiple strategies of
regenerative medicine for different diseases. More recently,
the artificial induction of stemness properties in adult
somatic cells has proposed a new way to generate stem
cells. One important concern of stem cell therapy is the
possible risk that transplanted stem cells could be rejected
by the recipient's immune system. Depending on their
source, stem cell transplantation is associated with diverse
immunological situations. If some sources allow autologous
transplantation, others cannot bypass an allogeneic context
between the donor and the recipient. This review summa-
rizes all of the stem cell sources for regenerative medicine
and the immunological questions associated to their use.
Regarding the emerging strategies compatible with autolo-
gous transplantation, this article points notably the com-
plexity of the choice between the immunological safety and
the specific advantages of allogeneic stem cells.
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Introduction: stem cells and stem cell therapy
Stem cells are found in all multicellular organisms. The
classical definition of a stem cell requires that it possess the
following two properties (i) self-renewal, which indicates the
ability to go through numerous cycles of cell division while
maintaining the undifferentiated state and (ii) potency, i.e., the
capacity to differentiate into specialized cell types. Potency can
cover various properties. Totipotency indicates the capacity to
differentiate into all embryonic and extra-embryonic cell types.
Such cells can construct a complete and viable organism.
Pluripotency indicates the ability to differentiate into nearly all
cells derived from any of the three germ layers. Multipotency
is restricted to a closely related family of cells (e.g., neural stem
cells differentiate into cells of the central nervous system). The
two broad types of stem cells found in vivo are: embryonic
stem cells that are isolated from the inner cell mass of early
embryos [1] and stem cells that are found in adult tissues and
called adult stem cells. In the developing embryo, embryonic
stem cells are dedicated to differentiate into all of the
specialized tissues. Adult stem cells act as a repair system
for the body, replenishing specialized cells, but also maintain
the normal turnover of regenerative organs. Induced plurip-
otent stem cells are a type of pluripotent stem cell artificially
derived from a non-pluripotent cell, typically an adult somatic
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cell, by inducing a forced expression of specific genes [2, 3].
Induced pluripotent stem cells resemble their natural embry-
onic stem cell equivalent.
Stem cell therapy is a type of intervention strategy that
introduces new cells into damaged tissue in order to treat
disease or injury. The ability of stem cells to self-renew and
give rise to subsequent generations with variable degrees of
differentiation capacities offers significant potential for
generation of tissues that can potentially replace diseased
and damaged areas in the body. Some adult stem cells from
umbilical cord blood and bone marrow are routinely used in
medical therapies. In the future, researchers anticipate being
able to use technologies derived from stem cell research to
treat a wider variety of diseases including, e.g., neurode-
generative disorders and brain and cardiac injury amongst a
number of other impairments and conditions. Depending on
their source, stem cells with a therapeutic potential could or
could not originate from the treated patient. As profiling of
the antigens expressed on stem cells and their derivatives
has revealed that they can express rejection antigens, an
immune reaction can occur when the donor is unrelated to
the recipient.
Different sources of stem cells for regenerative medicine
and their immunological potential
Embryonic stem cells
Embryonic stem cells are cell lines derived from the
inner cell mass of a blastocyst. A blastocyst is an early-
stage embryo (approximately 4 to 5 days old in humans)
consisting of 50–150 cells. It contains the trophectoderm
which gives rise to the placenta and the inner cell mass
which is dedicated to generate the embryo proper.
Embryonic stem cells result from the in vitro culture
of the inner cell mass, resulting in the proliferation of
pluripotent cells in culture [1]. Human embryonic stem
cell lines require a specific environment in order to
maintain them in vitro in an undifferentiated state.
Pluripotent cells of the inner cell mass give rise during
in vivo development to all derivatives of the three primary
germ layers: ectoderm, endoderm, and mesoderm [1].
Thus, human embryonic stem cells can be differentiated
in vitro into various cell types of the body, opening the
possibility of various transplantations. The currently
most-studied applications using embryonic stem cells
are heart failure [4], neurodegenerative disorders, brain
injury including Parkinson's disease and spinal cord
injury [5–8], and diabetes [9]. Due to the systematic
unrelated genetic origin between embryonic stem cells
and the recipient, there is a potential risk of transplant
rejection.
Adult stem cells
The term adult stem cell refers to any cell which is found in
a developed organism that has the two fundamental
properties of stem cells: the ability to divide and create
another cell like itself and also the ability to create a more
differentiated cell. Pluripotent adult stem cells are rare and
generally small in number, but can be found in a number of
tissues. Most adult stem cells are multipotent (lineage-
restricted) and are generally referred by their tissue origin.
Hematopoietic stem cells are found in the bone marrow
and give rise to all the blood cell types. Hematopoietic stem
cell transplantation has been successfully used for many
years to treat bone marrow disorders. In the case of
allogeneic adult stem cell transplantation, there are immu-
nological questions related to graft/recipient rejection that
must be considered [10]. However, in some instances,
hematopoietic stem cells can be obtained from the intended
recipient. In these autograft situations, the risk of rejection
is essentially non-existent. Adipose-derived stem cells have
been isolated from human fat, usually by liposuction.
Human adipose-derived stem cells have been shown to
differentiate into bone, cartilage, fat, and muscle, which
make them a possible source for future applications in the
clinic [11]. There are no immunological barriers for these
cell types if they are isolated from the recipient. Multipotent
stem cells have been successfully recovered from dental
pulp, the soft living tissue inside a tooth [12]. This
particular type of stem cell has the future potential to
differentiate into a variety of other cell types including
cardiac cells, neural cells, and bone and cartilage cells.
They are not associated with an immunological barrier if
they are isolated from the recipient. Mesenchymal stem
cells have been isolated from the placenta, adipose tissue,
lung, bone marrow, blood, and the umbilical cord [13].
They are of stromal origin and can differentiate into a
variety of tissues. Mesenchymal stem cells are particularly
attractive for clinical therapy not only due to their ability to
differentiate into various cell types, but also for their
immunosuppressive properties [14]. They are not system-
atically associated with an immunological barrier since they
can be isolated from the recipient. The existence of stem
cells in the fetal or adult brain has been discovered
following the observation that the process of neurogenesis,
the birth of new neurons, continues into adulthood. Neural
stem cells are commonly isolated and cultured in vitro as so
called “neural spheres”—a kind of cell aggregate contain-
ing a large proportion of neural stem cells. They can be
propagated for extended periods of time and differentiated
into cells of the central nervous system including neurons,
astrocytes, and oligodendrocytes [15]. Neural stem cells can
be isolated from either the fetal central nervous system or
from very restricted neurogenic regions now known to
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persist in two niches in the adult brain: one in the sub-
ventricular zone lining the lateral ventricles and the other in
the dentate gyrus of the hippocampus [16, 17]. Lineage-
restricted neural stem cells have been shown to be able to
integrate into the brain [18] and to elicit repair in animal
models, including Parkinson's disease [19], multiple sclerosis
[20], and ischemic stroke [21]. Neural stem cells for
replacement therapy applications are systematically unrelated
to the recipient because they originate in general from
aborted fetuses or surgical pieces from the brain of cadavers.
Thus, there is an immunological barrier for their use.
Olfactory stem cells have been successfully harvested from
the human olfactory mucosa, which are found in the lining
of the nose and are involved in the sense of smell. If they are
given to the right chemical environment, these cells have the
same ability to develop into many different cell types [22].
Olfactory stem cells hold the potential for therapeutic
applications and, in contrast to neural stem cells, can be
harvested with ease without harm to the patient context.
Thus, there are no immunological barriers associated with
this stem cell source.
Induced pluripotent stem cells derived from adult somatic
cells
It has been described in 2006 that the expression of a set of
only four genes (Klf4, Sox-2, Oct-4, and c-Myc) trans-
formed mouse somatic cells back into a pluripotent-like
state [3]. In cell culture, these first induced pluripotent stem
cells behaved like embryonic stem cells. Soon after was
described the successful generation of human induced
pluripotent stem cells by the same set of genes, with an
alternative gene combination composed of Oct-4, Sox-2,
Nanog, and Lin28 [2]. While the potential use of human
embryonic stem cells for therapeutic applications comes
with immunological problems similar to those encountered
during organ transplantation, reprogramming of somatic
cells theoretically promises to provide custom-made plu-
ripotent cells from individual patients.
Multipotent or pluripotent stem cell transplantation?
Pluripotent stem cells have theoretically the capacity to
generate all of the existing cell types in the body, whereas
multipotent stem cells are more restricted to defined
lineages. One inconvenience of some multipotent stem
cells is their availability. It is notably the case for fetal or
adult neural stem cells for which the number of aborted
fetuses or brain samples is limited. Moreover, several
aborted fetuses are generally required for one transplanted
patient [23]. In both cases, fetal or adult samples are a non-
standardized source of neural stem cells, leading to high
variability in the quality of transplants. On the contrary,
pluripotent stem cells have the advantage to be an indefinite
and more standardized source of cells for transplantation.
However, despite this advantage, pluripotent stem cells do
not share the same efficiency than multipotent stem cells for
differentiation. To date, it is still more complicated to
trigger pluripotent stem cells toward a defined cell type
than multipotent stem cells. Indeed, pluripotency is a very
immature stage. Thus, highly defined exogenous and
endogenous cues are required for the specific decision
to differentiate towards a precise cell type. As a
consequence, in vitro differentiation of pluripotent stem
cells generally requires more complicated and less
controlled culture conditions with a high risk of
dedifferentiation or incomplete differentiation. Unsuited
undifferentiated cells or foreign cells are dangerous for
the recipient because of a risk of tumors [24] or
inefficient transplantation. On the contrary, multipotent
stem cells are more mature and have already been
naturally specified towards a defined direction, rendering
them more suitable for the targeted differentiation in vitro,
with a lower risk of dangerous cell generation. Thus, there
is still a balance between the advantages and inconve-
nience of pluripotent versus multipotent stem cells,
opposing the availability of stem cells to the possibility
to efficiently differentiating them (Table 1).
Stem cell transplantations: multiple immunological
situations
Multiple strategies of stem cell transplantation are currently
studied. Some of them open the possibility of autologous
transplantations, whereas others are associated with alloge-
neic situations. Several situations do not expose the
transplant to rejection because the donor is also the
recipient. A simple approach consists in the isolation and
transplantation of stem cells in the same individual, without
any differentiation process ex vivo (Fig. 1a). This approach
is currently used in medicine in the context of autologous
hematopoietic stem cell transplantation, where the trans-
planted stem cells differentiate towards the bone marrow in
vivo after their injection. Numerous approaches consist of
the same principle, with the addition of an in vitro stem cell
differentiation step. In this context, stem cells are isolated,
differentiated in vitro towards the suited cell type, and re-
injected in the same patient (Fig. 1b). It is notably the case
for multipotent adult stem cells which have to be further
matured towards a defined cell type. Another autologous
context consists of the in vitro reprogramming of recipient
somatic cells towards induced pluripotent stem cells. The
reprogrammed cells are then differentiated towards the
suited cell type and transplanted (Fig. 1c). Theoretically,
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Table 1 Advantages and disadvantages of pluripotent versus multipotent stem cells
Autologous
transplantation
Allogeneic
transplantation
Advantages Disadvantages
Pluripotent embryonic
stem cells
Not possible In all cases Unlimited and standardized
source, can generate all cell types
Complexity of in vitro differentiation,
allogeneic source: risk of immune rejection,
risk of tumor, ethical questions
Induced pluripotent
stem cells
Possible Possible Allows autologous transplantation,
can generate all cell types, optimal
for cell banking according hla
Complexity of in vitro differentiation, risk of
tumor, genetic modifications
Adult neural
stem cells
Rare Possible Easier differentiation towards
suited cells, tumors are rare
Low availability of cells, non-standardized
source, allogeneic source: risk of immune
rejection
Fetal neural
stem cells
Not possible Possible Easier differentiation toward
suited cells, tumors are rare
Low availability of cells, non-standardized
source, strong risk of immune rejection
Hematopoietic
stem cells
Possible Possible Availability of transplants, autologous
or allogeneic context, low
manipulation of transplanted cells
Restricted differentiation potential
Adipose-derived
stem cells
Possible Possible Easy availability of transplants,
autologous or allogeneic context
Restricted differentiation potential
Mesenchymal
stem cells
Possible Possible Availability of transplants,
autologous or allogeneic context
Restricted differentiation potential
Olfactory adult
stem cells
Possible Possible Availability of transplants,
autologous or allogeneic context
Restricted differentiation potential
Dental pulp
stem cells
Possible Possible Availability of transplants,
autologous or allogeneic context
Restricted differentiation potential
Fig. 1 Multiple strategies of stem cell transplantation. a Isolation and
transplantation of stem cells in the same individual, without any
differentiation process ex vivo. b Stem cells are isolated, differentiated
in vitro towards the suited cell type, and re-injected in the same patient.
c The reprogrammed cells are then differentiated towards the suited cell
type and transplanted. In the allogeneic context, d adult stem cells can
be transferred from a donor to a recipient. e Allogeneic adult stem cells
can either be transplanted directly or further differentiated in vitro
towards the suited cell type before transplantation. f They also can be
generated from a donor, differentiated, and transplanted to a recipient. g
Other allogeneic contexts of cell transplantation are the use of stem cells
h or differentiated stem cells. i Embryonic stem cells cannot be directly
injected into patients because of the risk of teratomas [24], but need to
be differentiated towards the suited cell types
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this approach opens the possibility of autologous transplan-
tation of any cell types without any immune barriers.
The other concepts of stem cell therapy are associated
with an allogeneic context (Fig. 1). First, adult stem cells
can be transferred from a donor to a recipient (Fig. 1d).
This situation is necessary when adult stem cells cannot be
obtained from the recipient. It is the case for hematological
malignancies where the diseased bone marrow has been
destroyed to be replaced by hematopoietic stem cells from a
donor. It is also the case for adult neural stem cells that
generally cannot be isolated from the recipient. Allogeneic
adult stem cells can either be transplanted directly or be
further differentiated in vitro towards the suited cell type
before transplantation (Fig. 1e), depending on the applica-
tion. Although induced pluripotent stem cells have opened
the possibility of autologous transplantation, they also can
be generated from a donor, differentiated, and transplanted
to a recipient (Fig. 1f). There are indeed several arguments
to prefer allogeneic transplantation of induced pluripotent
stem cells (discussed in the next paragraph). The other
allogeneic contexts of cell transplantation are the use of
stem cells (Fig. 1g) or differentiated stem cells (Fig. 1h)
from aborted fetuses. It has been notably widely tested in
neurodegenerative disorders such as Parkinson's disease
where neural stem cells were isolated from the fetal
mesencephalon and transplanted into the diseased striatum
of patients [23]. One inconvenience of this approach was
the need of a high number of cells for each transplanted
patient, requiring the use of several aborted fetuses. In this
situation, the immunological risk is very high because of
the diversity of major and minor rejection antigens in the
transplant. Finally, embryonic stem cells are systematically
from an allogeneic origin because of the use of spared
embryos to generate lines. Embryonic stem cells cannot be
directly injected into patients because of the risk of
teratomas [24], but need to be differentiated towards the
suited cell types (Fig. 1i).
Patient-specific or characterized stem cell lines?
Autologous stem cell transplantation has the advantage of
immunological safety. Does it mean that this option must be
systematically preferred when the nature of stem cells offers
this possibility? In fact, there are some reasons to doubt this
assumption because autologous transplantation is also
associated with some risks.
First, stem cells isolated or generated from a donor are
not systematically efficient to differentiate and cure the
disease. Indeed, a high variability in the differentiation
potential of different pluripotent stem cell lines is well
known [25–28]. It means that, for example, a unique
induced pluripotent stem cell line derived from a patient
could be inefficient to produce a defined cell type for
transplantation. Second, stem cells for transplantation must
be highly characterized. Numbers quality controls to ensure
the safety of therapeutic cells must be performed before
transplantation, including, e.g., the microbial safety and the
control of their tumorigenic potential. Validation of these
safety controls takes time and involves numerous laborato-
ries. To solve these limitations, numerous stem cell lines
should be derived from one patient and then fully
characterized before the selection of the most safe and
efficient ones. However, in the context of autologous
transplantation, such heavy and long procedures would be
difficult to adapt to clinical-grade conditions and would not
be compatible with cell therapy applications for which stem
cells must be transplanted in a very short delay after injury
(e.g., spinal cord lesions) [29]. Thus, if autologous
transplantation is theoretically possible for some stem cell
sources, there could be more advantages to favor allogeneic
approaches for which characterized, efficient, and safe lines
have been stored and are readily available. Finally, the
genetic status of transplanted cells must also be considered
in the context of autologous stem cell transplantation.
Because of the genetic origin of some diseases, the
following question is opened: Does autologous stem cell
transplantation consist in the reintroduction of diseased
cells in the same patients? In other words, is there a risk of
relapse of the disease in the graft? If progression of the
disease within the graft has been reported independently of
the genetic status of transplanted cells [30], there are still no
data to answer to this question, and further studies are
needed to address this point.
Stem cell transplantation and immunosuppressive drugs
Because of the situations associated with a risk of immune
rejection, the question of pharmacological immune
suppression after stem cell transplantation is relevant.
Immunosuppressive agents are drugs that inhibit or
prevent activity of the immune system. Because the
majority of them are very active on cell physiology and
act non-selectively on the immune system, there are
generally strong side effects on the patients. For
example, ciclosporin or glucocorticoids interfere with
the transcription of numerous genes, cytostatic agents
inhibit cell proliferation, etc.
In addition to side effects on the patient and because of
their generally strong activity on cells, immunosuppressive
drugs could also be associated with side effects on the
grafted cells. Indeed, in numerous situations, undifferenti-
ated or pre-differentiated stem cells, depending on their
source, must continue and finish their differentiation
program after transplantation. As this terminal maturation
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of cells requires multiple intracellular events combining
transduction pathways and gene expression, it cannot be
excluded that some immunosuppressants will alter this
process and decrease graft efficiency. A recent study
showed that ciclosporin and dexamethasone strongly
inhibited in vitro the terminal maturation of neural
progenitor cells toward mature neurons [31], confirming
that the possible interference between drugs and trans-
planted cells needs to be carefully evaluated.
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